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Abstract
Introduction: The purpose of the present manuscript is to test the hypothesis that arthrotropic localization and
synovial cell internalization account for the unique capacity of N-(2-hydroxypropyl)methacrylamide (HPMA)
copolymer-dexamethasone conjugate (P-Dex, a macromolecular prodrug of dexamethasone) to induce sustained
amelioration of joint inflammation and inhibition of tissue damage in an animal model of inflammatory arthritis.
Methods: Rats with adjuvant-induced arthritis (AA) were treated with P-Dex, free dexamethasone, saline or HPMA
homopolymer. To define the biodistribution of P-Dex, conjugates with different imaging labels were given to AA
rats and analyzed. Isolated joint tissues were evaluated by fluorescence-activated cell sorting (FACS) and
immunohistochemical staining. Cellular uptake of P-Dex and its effects on apoptosis and production of
proinflammatory cytokines were examined using human monocyte-macrophages and fibroblasts.
Results: A single systemic administration of P-Dex completely suppressed AA for >20 days. Magnetic resonance
imaging demonstrated higher HPMA copolymer influx into the inflamed joints than the normal joints.
Immunohistochemistry and FACS analyses of arthritic joints revealed extensive uptake of the polymer conjugate by
synovial fibroblasts and myeloid lineage cells. The capacity of P-Dex to suppress inflammation was confirmed in
monocyte-macrophage cultures in which P-Dex treatment resulted in suppression of lipopolysaccharide-induced
IL-6 and TNFa release. Similarly, TNFa-induced expression of matrix metalloproteinases (MMP1 and MMP3) in
synovial fibroblasts from a rheumatoid arthritis patient was suppressed by P-Dex. P-Dex showed no detectable
effect on monocyte apoptosis.
Conclusions: P-Dex provides superior and sustained amelioration of AA compared with an equivalent dose of free
dexamethasone. The arthrotropism and local retention of P-Dex is attributed to the enhanced vascular permeability
in arthritic joints and the internalization of P-Dex by synovial cells. The uptake and processing of P-Dex by
macrophages and fibroblasts, and downregulation of proinflammatory mediators, provides an explanation for the
sustained anti-inflammatory efficacy of P-Dex in this model of inflammatory arthritis.
Introduction
Therapeutic strategies targeting cellular components of
the inflamed synovial tissue and blockage of specific
inflammatory mediators have been shown to be
efficacious in ameliorating inflammation and inhibiting
joint destruction in patients with rheumatoid arthritis
(RA) [1,2]. From a pharmacodynamic perspective, the
treatment efficacy mainly depends upon two factors:
the specificity of the drug to its molecular target, and
the local concentration of the drug where it interacts
with its putative target. While most of the efforts to
improve RA treatment have been focused on the
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pathways and more potent therapeutic agents, the
approach to manipulate the local drug concentration in
the synovium and consequently potentiate the efficacy
of a particular therapy has been very limited [3-5].
In the past decade, several groups have developed
liposomal and protein-based formulations to facilitate
the targeting of drugs to arthritic joints [6-9]. Recently,
our team has developed the acid-labile arthrotropic
macromolecular dexamethasone prodrug based on N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer
( P - D e x )[ 1 0 ]a n dh a sp r o v i d e dp r e l i m i n a r ye v i d e n c e
demonstrating its superior anti-inflammatory efficacy
compared with an equivalent dose of free dexametha-
sone (Dex) [11-13]. The present studies were underta-
ken to delineate the mechanisms involved in the
arthrotropism and joint retention of P-Dex, and its
capacity to produce sustained amelioration of inflamma-
tory arthritis.
Materials and methods
Treatment of adjuvant-induced arthritis rats with P-Dex
Adjuvant-induced arthritis (AA) rats were induced as
described previously [11]. On day 14 post induction,
the rats were randomized into five groups (eight rats/
group): P-Dex half-dose (equivalent Dex dose = 5 mg/
kg, single intravenous (i.v.) injection), P-Dex (equiva-
lent Dex dose = 10 mg/kg, single i.v. injection) [13],
free Dex (total dose = 10 mg/kg, four intraperitoneal
injections, days 14 to 17), saline (single i.v. injection)
and HPMA polymer without Dex (PHPMA, single i.
v. injection; amount of polymer used is equivalent to
P-Dex).
Arthritis flare of the P-Dex group was set as the
experimental endpoint, at which time the hind limbs
were isolated for bone mineral density (BMD) and his-
tology evaluations. The BMD was measured from the
distal tibia to the phalanges of the paw using a pDEXA®
Sabre™ X-ray bone densitometer (Norland Medical Sys-
tem, Inc., Fort Atkinson, WI, USA).
All animal experiments were performed according to
a protocol approved by the University of Nebraska
Medical Center Institutional Animal Care and Use
Committee.
Clinical measurements
The articular index score was measured during the
treatment as described previously [13]. The scores were
applied to each hind limb by the same observer (LDQ)
from day 8 to day 34 post-arthritis induction, and the
sum of the two hind limb scores for each animal were
recorded. The ankle diameter (medial to lateral) was
measured using a digital caliper (World Prescision
Instruments, Inc., Saraspta, FL, USA).
Histological analysis
The isolated hind limbs were fixed with buffered formalin
and were decalcified. Thin sections (5 μm) were cut
approximately 200 μma p a r ta n dw e r eH&Es t a i n e d .
The joints were histologically graded by a pathologist
(SML), who was blind to the treatment groups, using a
scoring system adapted from previous work [13]. Each
histopathologic feature was graded as follows: synovial
cell lining hyperplasia (0 to 2); pannus formation (0 to 3);
mononuclear cell infiltration (0 to 3); polymorphonuclear
leukocytes infiltration in periarticular soft tissue (0 to 3);
cellular infiltration and bone erosion at distal tibia (0 to
3); and cellular infiltration of cartilage (0 to 2). The score
for every histopathologic feature was summed for each
animal.
Quantitative analysis of joint vascular leakage using
magnetic resonance imaging
High-resolution T1-weighted magnetic resonance ima-
ging (MRI) scans and T1 maps were acquired before
and after (every 10 minutes for 4 hours) the injection of
DOTA-Gd
3+-labeled HPMA copolymer (P-DOTA-Gd
3+)
[11]. All MRI scans were performed on a Bruker Avance
MRI and spectroscopy system (7T/21 cm; Bruker,
Karlsruhe, Germany). T1 maps were acquired using a
Look-Locker technique [14]. Patlak plots were used to
estimate the tissue transfer constant of P-DOTA-Gd
3+
(Ki). T1 and Ki maps were reconstructed using the neu-
ropipes software suite (a software suite written in ‘C’ for
the apodization, reconstruction, and curve-fitting of
MRI images. Developed by Dr. James Ewing at Henry
Ford Hospital, Detroit, MI, USA). Both unidirectional
and bidirectional transfer models were used in the ana-
lyses. F-tests were performed between the two models,
and each model was tested against no leakage on a
pixel-by-pixel basis [15].
Biodistribution of
125I -labeled P-Dex
Tyrosine amide-containing P-Dex (P-Dex-Tyr-NH2) was
iodinated using a standard chloramine T method [16].
For the biodistribution study,
125I-labeled P-Dex-Tyr-
NH2 (mixed with P-Dex-Tyr-NH2 without
125I, Dex
equivalent dose = 5 mg/kg) was administered to AA rats
and healthy rats (six rats/group) via tail vein injection.
The animals were euthanized 24 hours post administra-
tion. Major organs and tissues were collected and evalu-
ated with a g-counter (Minaxi Auto-gamma 5000 series;
Packard Instrument Company, Meriden, CT, USA).
Immunohistochemical analysis of arthritic joints
In the MRI studies, HPMA copolymer labeled with
Alexa Fluor® 488 (P-Alexa) was given to AA rats simul-
taneously with P-DOTA-Gd
3+. At 24 hours post injec-
tion, hind limbs were isolated and fixed with 0.5%
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ethylenediamine tetraacetic acid. Tissues were paraffin
embedded and sections corresponding to the MRI hot-
spots were selected for immunohistochemical analysis.
After deparaffinization, the sections were incubated for
30 minutes with citrate buffer (10 mM, pH = 6.0) at 95°
C, followed by incubation with 10% goat serum/PBS for
20 minutes at room temperature. After addition of the
primary antibodies (CD68 (10 μg/ml) or prolyl 4-hydro-
xylase (10 μg/ml), diluted in 10% goat serum/PBS), the
sections were incubated overnight at 4°C in a humidified
chamber. After washing with PBS (three times), diluted
phycoerythrin-labeled rabbit anti-mouse IgG secondary
antibody (5 μg/ml) was added and incubated for 30
minutes in the dark at room temperature. In control
experiments, primary antibodies were replaced by PBS
and the samples were processed as described above. The
processed tissue sections were then evaluated with con-
focal microscopy.
Fluorescence-activated cell sorting analysis of cells
isolated from synovial tissue
At 14 days post induction, P-Alexa was given to AA rats
by tail vein injection. At 24 hours post injection, ankle
joint-associated soft tissues were surgically removed
with a scalpel and minced aseptically. The tissues were
further digested with collagenase type I (1 mg/ml;
Sigma-Aldrich, St Louis, MO, USA) at 37°C for 30 min-
utes. After passing through a 70 μmc e l ls t r a i n e r ,as i n -
gle-cell suspension (2 × 10
6/ml) was obtained. ACK
Lysing Buffer (Quality Biological, Gaithersburg, MD,
USA) was then used to remove blood cells.
For FACS evaluation, the cells were first incubated
respectively with three primary antibodies - CD68
(1:100 dilution; AbD Serotec, Raleigh, NC, USA), CD11c
(1:10 dilution; abcam Inc., Cambridge, MA, USA) and
prolyl-4-hydroxylase (1:50 dilution; Acris Antibodies,
Herford, Germany) - each for 30 minutes on ice. The
cells were then incubated with phycoerythrin-labeled
rabbit anti-mouse IgG secondary antibody (1:100 dilu-
tion; BD Biosciences, San Jose, CA, USA) for another 30
minutes on ice. Isotype-matched mouse IgG1 and
mouse IgG2a (BD Biosciences) were used as negative
controls. Following the final wash, the cells were ana-
lyzed with flow cytometry.
Macrophage and fibroblast cultures
CD14-positive monocytes were prepared from peripheral
blood mononuclear cells derived from de-identified nor-
mal human donors as described previously [17]. Cells
were cultured for 24 hours at a cell density of 10
6/ml in
a-MEM medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% FBS (VWR, West Chester, PA,
USA) and 1% antibiotic/antimycotic (Invitrogen) in the
presence of 10 ng/ml human macrophage colony-stimu-
lating factor (Peprotech, Rocky Hill, NJ, USA) in 24-well
tissue culture plates (1 ml/well). Cells were then pulsed
for 4 hours with P-Dex (5 μM) or Dex (0.6 μM), washed
and replenished with fresh medium. The two treatments
had equivalent doses of Dex.
After 24 hours, cells were either analyzed by confocal
microscopy and flow cytometry or challenged with
inflammatory mediators. For confocal microscopy, the
lysosomal and nuclear compartments were stained with
LysoTracker Red DND-99 and Hoechst 33342 (Invitro-
gen), respectively. For flow cytometric analysis of apop-
tosis, cells were analyzed using the Vybrant Apoptosis
Assay Kit #3 (Invitrogen) in accordance with the manu-
facturer’s recommendations. For inflammatory challenge,
cells were treated with 40 pg/ml lipopolysaccharide
(LPS) for 6 hours, after which conditioned media were
analyzed for inflammatory cytokine production (that is,
TNFa and IL-6) by ELISA (BD Bioscience, San Diego,
CA, USA).
Fibroblasts were isolated from periprosthetic tissues
retrieved from patients undergoing total hip replace-
ment revision surgery and from synovial membranes of
RA patients. After digestion with collagenase (5 mg/ml),
fibroblasts were obtained by passing through a 70 μm
cell strainer. The cells were subsequently cultured at a
density of 5 × 10
4/ml in a-MEM medium supplemented
with 10% FBS and 1% antibiotic/antimycotic in 24-well
tissue culture plates (1 ml/well).
Treatment with Dex or P-Dex and confocal micro-
scopy were performed as described above for mono-
cytes. For inflammatory challenge, fibroblasts were
incubated for 24 hours with 100 ng/ml human TNFa
(Peprotech), following which conditioned media were
analyzed for prostaglandin E2 by ELISA (BD Bioscience)
and total cellular RNA was prepared (RNeasy Mini Kit,
QIAGEN, Inc., Valencia, CA, USA) and analyzed by
real-time RT-PCR for matrix metalloproteinases (MMP1
and MMP3) expression.
All human cells experiments were approved by the
Institutional Review Board of Hospital for Special
Surgery.
Statistical methods
One-way analysis of variance was used in the data analy-
sis, followed by a post hoc test (Student-Newman-Keuls)
for multiple comparisons using Instant Biostatistics
(GraphPad Software, La Jolla, CA, USA). P <0 . 0 5w a s
considered statistically significant.
Results
Sustained amelioration of joint inflammation by P-Dex
As shown in Figure 1a, b, the AA rats respond to free
Dex and P-Dex (10 mg/kg) treatment immediately with
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Dex, a flare in joint inflammation was observed immedi-
ately upon cessation of the treatment; and by the end of
the study, free Dex, PHPMA and the saline groups all
had similar ankle diameter and articular index scores. In
contrast, administration of single-dose P-Dex provided a
sustained and dose-dependent amelioration of joint
inflammation that lasted for 20 days, when minor signs
of joint swelling was found in two rats of the P-Dex
group.
Bone mineral density assessment
The saline, PHPMA and free Dex groups had lower
mean ankle joint BMD values of 0.17 to 0.18 g/cm
2,
while the P-Dex-treated (10 mg/kg and 5 mg/kg) groups
and healthy groups maintain higher mean BMD values of
0.19 to 0.2 g/cm
2. The statistical analyses indicated that
the average BMD values of P-Dex groups (10 mg/kg and
5 mg/kg) were significantly higher (P < 0.05) than those
of the saline, PHPMA or free Dex-treated groups
(Figure 1c).
Histological evaluation of ankle joints
As shown in Figure 1d, both P-Dex groups had low
average histology scores. No significant difference was
found between high-dose P-Dex and the healthy control.
The histology scores for the free Dex, saline and
PHPMA groups were much worse (>11). Figure 2 shows
that both P-Dex treatments preserve bone and cartilage,
with findings similar to the healthy control. Saline and
Figure 1 Treatment of adjuvant-induced arthritis rats with a macromolecular prodrug of dexamethasone. The treatment of adjuvant-
induced arthritis (AA) rats (eight rats/group) with acid-labile N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-dexamethasone conjugate
(P-Dex), half-dose P-Dex, free dexamethasone (Dex), HPMA polymer without Dex (PHPMA) and saline were summarized in this figure. An
untreated healthy control group was also included. (a) Changes in AA rat ankle diameters during the treatment. (b) Changes in articular index
score of the animals during the treatment. (c) Endpoint bone mineral density (BMD) of the ankle joints for all the animal groups. (d) Average
histology scores of the ankle joints from the six animal groups. ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant.
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in each category of the histological grading. Synovial
cell lining hyperplasia, pannus formation, polymor-
phonuclear leukocytes infiltration in periarticular soft
tissue, cellular infiltration of cartilage, cellular infiltra-
tion and bone destruction at the distal tibia were pre-
sent in all cases. For the free Dex group, only one out
of eight rats was found with a relatively low histology
score.
Quantitative analysis of joint vascular leakage using
magnetic resonance imaging
Using a Patlak plot, a Ki map was constructed and
superimposed with the maximum intensity projection
image at different angles (Figure 3a; see also Additional
file 1 for movie). The region with the highest Ki was
associated with the inflamed synovium region close to
the distal tibia where there was evidence of severe bone
and cartilage erosion. An average ki value of 0.0032/min
was obtained based on evaluation of three AA rats. The
Ki for healthy rats was close to zero.
Biodistribution of P-Dex
Quantitative biodistribution data for
125I-labeled P-Dex-
Tyr-NH2 in both AA and healthy rats were acquired at
24 hours post treatment (Figure 3b). Similar percentages
of the injected dose per gram of tissue were found in
most tissues isolated from healthy and AA rats except
the ankle joints and blood. Arthritic joints showed a
significantly higher P-Dex distribution compared with
the healthy joints (P < 0.0001).
Immunohistochemical analysis
As shown in Figure 4, there was extensive uptake of
P-Alexa by synovial cells with primary localization to
intracellular vesicles. Immunohistochemical staining of the
sections prepared from inflamed joints with anti-CD68 or
anti-prolyl-4-hydroxylase antibodies revealed co-localiza-
tion of P-Alexa-positive intracellular vesicles with both
macrophage-like (CD-68-positive) and fibroblast-like (pro-
lyl-4-hydroxylase-positive) synoviocytes. The double-
stained cells could be found throughout the synovium but
were particularly abundant within the synovial lining.
FACS analysis of HPMA copolymer internalization by AA
rat synoviocytes
As shown in Figure 5, FACS analysis revealed that >30%
of the cells disaggregated from the AA rat synovial tis-
sue were P-Alexa-positive. The P-Alexa-positive cells
included subpopulations of cells that were CD68-posi-
tive (5.1%, isotype control corrected), CD11c-positive
(12.6%, isotype control corrected) or prolyl-4-hydroxy-
lase-positive (7.6%, isotype control corrected).
Confocal microscopic analysis of P-Dex internalization
and subcellular partitioning by inflammatory cells
To define the intracellular localization following uptake
of P-Dex in macrophage lineage and fibroblastic cells,
Figure 2 Light micrographs (magnification, 100x) of ankle joint histology for the six animal groups. Synovial lining and villous
hyperplasia, cellular infiltration in periarticular soft tissue, bone and cartilage destruction are clearly evident in the free dexamethasone (Dex), the
N-(2-hydroxypropyl)methacrylamide polymer without Dex (PHPMA) and the saline groups. P-Dex, acid-labile N-(2-hydroxypropyl)methacrylamide
copolymer-dexamethasone conjugate.
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and fibroblasts were prepared from the synovial-like tis-
sues of patients undergoing revision surgery for prosthe-
tic loosening after joint replacement. Confocal
fluorescence microscopic images (Figure 6a, b), demon-
strate co-localization of the FITC-labeled prodrug with
the lysosomal marker DND-99 in both cell types. This
localization was also maintained during subsequent cul-
turing (not shown).
P-Dex inhibits LPS or TNFa induced release of
proinflammatory products in human monocytes and
fibroblasts
To demonstrate the effect of P-Dex on production of
proinflammatory mediators, monocytes were preincu-
bated with P-Dex or Dex for 4 hours and then
challenged with LPS. As shown in Figure 6c, d, pretreat-
ment with P-Dex or Dex resulted in marked inhibition
of LPS-induced TNFa and IL-6 production. Comparable
inhibition of TNF-induced expression of MMP1 and
MMP3 (Figure 6e) and prostaglandin E2 production
(data not shown) was also observed in RA synovial
fibroblasts pretreated with P-Dex or Dex. Finally, mono-
cyte apoptosis was unchanged from basal levels follow-
ing uptake of both P-Dex and Dex (Figure 6f).
Discussion
In preliminary studies, we reported that a single dose of
P-Dex (synthesized by either polymer analogues reaction
or Dex-containing monomer copolymerization) could
result in more potent resolution of joint inflammation
compared with free Dex [12,13]. In the current
Figure 3 Arthrotropism of N-(2-hydroxypropyl)methacrylamide copolymer conjugates. (a) Maximum intensity projection images (black
and white) of a representative adjuvant-induced arthritis (AA) rat right-hind limb from different angles (anterior, lateral and posterior),
superimposed with a tissue transfer constant of P-DOTA-Gd
3+ (Ki) map (color). Inserted color bar represents the color code for Ki values in the
map from 0 to 0.005/min. (b) Biodistribution of
125I-labeled acid-labile N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugate
(P-Dex) in healthy rats (open bars) and in AIA rats (solid bars) at 24 hours post administration.
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Page 6 of 10Figure 4 Immunohistochemical staining of sections from inflamed joints with anti-CD68 or anti-prolyl-4-hydroxylase antibodies.
Representative confocal microscopic images of (a) anti-CD68 and (b) anti-prolyl-4-hydroxylase immunohistochemical staining of decalcified,
Alexa Fluor® 488-labeled N-(2-hydroxypropyl)methacrylamide copolymer (P-Alexa)-treated adjuvant-induced arthritis (AA) rat ankle joint sections
are summarized in this figure. Each panel is composed of four sub-images: antibody red staining, P-Alexa green signal, differential interference
contrast (DIC) image and the co-localization of the three. The co-localization of red and green color in both panels yields a yellow color, which
confirms the uptake of the HPMA copolymer conjugate by CD68-positive (macrophage-like) or prolyl-4-hydroxylase-positive (fibroblast-like)
synoviocytes in AA rat ankle joints.
Figure 5 Fluorescence-activated cell sorting analysis of cells isolated from adjuvant-induced arthritis rat synovial tissue.T w e n t y - f o u r
hours after systemic administration of N-(2-hydroxypropyl)methacrylamide copolymer labeled with Alexa Fluor® 488 (P-Alexa), cells were isolated
from adjuvant-induced arthritis rat synovial tissue for fluorescence-activated cell sorting (FACS) analysis. IgG1 was used as control for CD68 and
prolyl-4-hydroxylase. IgG2a was used as control for CD11c. The result for IgG2a is similar to that for IgG1 with the upper right quadrant detected
at 2.45% (data not shown).
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established the full time course of sustained anti-inflam-
matory efficacy for P-Dex (>20 days), which is accompa-
nied by protection from both bone and cartilage
destruction. In addition, we demonstrated the intracellu-
lar localization of P-Dex in synovial cells after systemic
delivery and established its efficacy in inhibiting proin-
flammatory cytokine release.
The rationale for the use of the HPMA copolymer as
a drug-targeting vehicle is based on observations indi-
cating that synovial inflammation is associated with
enhanced vascular permeability to macromolecules [18].
Our MRI data using P-DOTA-Gd
3+ quantitatively con-
firmed the enhanced vascular permeability of the syno-
vial tissues to the HPMA copolymers and provides an
explanation for its unique arthrotropism. Of interest, the
Figure 6 Internalization and biological effects of acid-labile N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugate
in cultured human cells. Confocal images show the internalization and lysosomal localization of FITC-labeled acid-labile N-(2-hydroxypropyl)
methacrylamide copolymer-dexamethasone conjugate (P-Dex) by (a) cultured human monocytes and (b) fibroblasts. In the human monocyte
cultures, the internalized P-Dex represses lipopolysaccharide (LPS)-mediated production of (c) TNFa and (d) IL-6 to levels comparable with those
found with free dexamethasone (Dex) (n =3 ,P < 0.0002). (e) In synovial fibroblasts from a rheumatoid arthritis patient, P-Dex suppresses TNFa-
induced expression of matrix metalloproteinases (MMP1 & MMP3) mRNA. (f) Human monocyte apoptosis was detected in untreated monocytes
(upper left panel), and was greatly increased after serum withdrawal for 24 hours (upper right panel). Neither Dex (lower left) nor P-Dex (lower
right) increased apoptosis above basal levels.
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proximity to regions that histologically were associated
with the most severe bone and cartilage damage. This
suggests that there is a relationship between the quanti-
tative delivery of the polymer-based prodrug and the
severity of synovitis, with preferential localization of the
prodrug at sites of maximal inflammation. The MRI
results were confirmed by biodistribution studies using
125I-labeled HPMA copolymer-dexamethasone conjugate
(P-Dex-Tye-NH2-
125I). These results provided quantita-
tive affirmation that the distribution of P-Dex at 24
hours post administration was four or five times higher
in the AA rat ankle joints compared with healthy joints.
Previous studies have not provided an explanation for
the retention of macromolecules at sites of inflamma-
tion. To address this issue, we studied the cellular locali-
zation of the prodrug within inflamed joints after
systemic administration of Alexa Fluor® 488-labeled
HPMA copolymer (P-Alexa). Histologic analysis of
inflamed joints revealed that P-Alexa was internalized
by synoviocytes. Immunohistochemical and FACS ana-
lyses identified these cells as type A synoviocytes
(macrophage-like), type B synoviocytes (fibroblast-like)
and dendritic cells. The internalization of different
HPMA copolymers by murine macrophages and fibro-
blasts has been reported previously [19,20]. The interna-
lization and subcellular partitioning of P-Dex, however,
have not been evaluated. Our studies utilizing FITC-
labeled P-Dex and immunohistochemical staining with
the lysozomal marker DND-99 confirmed the co-locali-
zation of the macromolecular prodrug in a lysosomal
compartment consistent with internalization via an
endocytic pathway, and flow cytometric analysis showed
that P-Dex uptake did not induce apoptosis. HPMA
copolymers such as P-Dex are water-soluble polymers,
and thus are restricted by the lysosomal membrane
from escaping the endosome/lysosome compartments
once internalized by the cells. Within these subcellular
vesicles, P-Dex is exposed to an acidic environment (pH
~5.5); and since the Dex is conjugated to the HPMA
copolymer via an acid-labile hydrazone bond, the pro-
drug is subject to gradual hydrolysis and subsequent
release of the active drug [12]. The presence of intracel-
lular prodrug activation was confirmed by the capacity
of the internalized P-Dex to inhibit TNFa and IL-6
release from LPS-treated macrophages and to reduce
expression of MMP1 and MMP3 in RA synovial fibro-
blasts. Protective effects of P-Dex treatment were main-
tained for at least 7 days after exposure to cells in vitro.
We speculate that the sustained therapeutic effect
observed in the P-Dex treatment is due to the prolonged
residence of P-Dex within the synoviocytes and their
gradual low pH-triggered activation within lysosomes,
followed by the release of free Dex into the cytosol.
Conclusions
The data presented in this work support the conclusion
that the superior and long-lasting (>20 days) therapeutic
effects of single-dose P-Dex may be attributed to two
key factors. First, the enhanced vascular permeability in
the inflamed joints facilitates the arthrotropism of the
macromolecular prodrug. Second, the dynamic uptake
of the prodrug by activated synoviocytes and subsequent
trafficking to an acidic lysosomal compartment provides
an environment in which there is gradual local prodrug
activation and release of active drug resulting in sus-
tained anti-inflammatory signaling through blockade of
proinflammatory cytokine production. This is the first
report of an enhanced permeability and retention effect
of a macromolecular prodrug in an inflammatory dis-
ease. Of interest, this retention mechanism is fundamen-
t a l l yd i f f e r e n tf r o mt h ee n h a n c e dp e r m e a b i l i t ya n d
retention effect associated with solid tumors [21]. The
combined capability of time-dependent drug activation/
release at sites of disease pathology and selective deliv-
ery of therapeutic agents to sites of joint inflammation
establishes a novel pathway for the future design and
development of therapies for patients with RA and
related forms of inflammatory diseases.
Additional material
Additional file 1: Severe vasculature leakage associated with
adjuvant-induced arthritis (AA) rat joint. A movie demonstrating the
tissue transfer constant (Ki) (color) of the HPMA copolymer conjugate
labeled with DOTA-Gd
3+ (P-DOTA-Gd
3+) in a representative AA rat right-
hind limb, superimposed with a maximum intensity projection (MIP)
image (black and white) of the same limb. The inserted color bar
represents the color code for Ki values in the map from 0 to 0.005/min.
Higher vascular leakage was found to be associated with the soft tissue
around the distal tibia.
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